NASDAQ:ARYD ARYA Sciences Acquisition Corp IV (ARYD) Stock Price, News & Analysis → A once-in-a-century investment opportunity (From Stansberry Research) (Ad) Free ARYD Stock Alerts $11.40 +0.03 (+0.26%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$11.37▼$11.4050-Day Range$11.23▼$11.4052-Week Range$10.45▼$11.40Volume2,876 shsAverage Volume43,430 shsMarket Capitalization$85.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsShort InterestSocial Media Get ARYA Sciences Acquisition Corp IV alerts: Email Address Ad Stansberry ResearchA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead.To get its name and ticker symbol for free - just click here. About ARYA Sciences Acquisition Corp IV Stock (NASDAQ:ARYD)Arya Sciences Acquisition Corp IV does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring North American or European companies in the life sciences and medical technology sectors. The company was incorporated in 2020 and is based in New York, New York.Read More ARYD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARYD Stock News HeadlinesFebruary 14, 2024 | msn.comAdagio Medical to go public in $113M deal with SPAC ARYA SciencesFebruary 14, 2024 | finance.yahoo.comAdagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesFebruary 14, 2024 | prnewswire.comAdagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesApril 7, 2023 | marketwatch.com8-K: ARYA Sciences Acquisition Corp IVFebruary 24, 2022 | benzinga.comARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus' Gene Therapy Business Due to Market ConditionsNovember 30, 2021 | finance.yahoo.comMoore Kuehn Encourages KOR, DISCA, FTSI, and ARYD Investors to Contact Law FirmNovember 9, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of EJF, HTPA, ARYD, and ADER MergersOctober 6, 2021 | finance.yahoo.comMoore Kuehn Encourages NOTV, ARYD, XLRN, and TGP Investors to Contact Law FirmOctober 1, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of ARYA Sciences Acquisition Corp. IV MergerSeptember 30, 2021 | entrepreneur.comAmcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYASeptember 30, 2021 | msn.comAmicus Therapeutics Stock Rises; Sells Unit Stake in SPAC DealSeptember 30, 2021 | finance.yahoo.comAmicus stock is up 5%, the day after announcing plans to sell its gene therapy businessSeptember 29, 2021 | finance.yahoo.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of ARYA Sciences Acquisition Corp IV (Nasdaq - ARYD)September 29, 2021 | feeds.benzinga.comPerceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy BusinessSeptember 29, 2021 | apnews.comAmicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a ...September 29, 2021 | finance.yahoo.comAmicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”See More Headlines Receive ARYD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARYA Sciences Acquisition Corp IV and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:ARYD CUSIPN/A CIK1838821 Webwww.perceptivelife.com Phone212-284-2300FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-9.83% Return on Assets-5.41% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.49) per share Price / Book-3.27Miscellaneous Outstanding Shares7,540,000Free Float3,508,000Market Cap$85.96 million OptionableNot Optionable Beta-0.01 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Adam Leo Stone (Age 44)CEO & Director Mr. Michael Seth Altman CFA (Age 42)CFO & Director Mr. Konstantin Poukalov (Age 40)Chief Business Officer Key CompetitorsFuture Health ESGNASDAQ:FHLTForianNASDAQ:FORASpero TherapeuticsNASDAQ:SPROProtalix BioTherapeuticsNYSE:PLXIMACNASDAQ:IMACView All CompetitorsInstitutional OwnershipShaolin Capital Management LLCSold 150,000 shares on 5/17/2024Ownership: 1.588%Berkley W R CorpBought 130,598 shares on 5/16/2024Ownership: 4.237%Affinity Asset Advisors LLCBought 133,500 shares on 5/15/2024Ownership: 1.771%K2 Principal Fund L.P.Bought 39,248 shares on 5/14/2024Ownership: 0.521%Periscope Capital Inc.Sold 225,000 shares on 5/13/2024Ownership: 0.995%View All Institutional Transactions ARYD Stock Analysis - Frequently Asked Questions How have ARYD shares performed in 2024? ARYA Sciences Acquisition Corp IV's stock was trading at $10.90 on January 1st, 2024. Since then, ARYD shares have increased by 4.6% and is now trading at $11.40. View the best growth stocks for 2024 here. When did ARYA Sciences Acquisition Corp IV IPO? ARYA Sciences Acquisition Corp IV (ARYD) raised $130 million in an initial public offering (IPO) on Friday, February 26th 2021. The company issued 13,000,000 shares at $10.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO. Who are ARYA Sciences Acquisition Corp IV's major shareholders? ARYA Sciences Acquisition Corp IV's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Berkley W R Corp (4.24%), Mizuho Securities USA LLC (3.21%), Affinity Asset Advisors LLC (1.77%), Shaolin Capital Management LLC (1.59%), Periscope Capital Inc. (0.99%) and K2 Principal Fund L.P. (0.52%). How do I buy shares of ARYA Sciences Acquisition Corp IV? Shares of ARYD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARYD) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchShocking $16T Elon Musk Crypto LeakCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlace[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARYA Sciences Acquisition Corp IV Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
